Inhaled heparin in cystic fibrosis

Serisier, D. J., Shute, J. K., Hockey, P. M., Higgins, B., Conway, J. and Carroll, M. P. (2006) Inhaled heparin in cystic fibrosis. European Respiratory Journal, 27 2: 354-358. doi:10.1183/09031936.06.00069005

Author Serisier, D. J.
Shute, J. K.
Hockey, P. M.
Higgins, B.
Conway, J.
Carroll, M. P.
Title Inhaled heparin in cystic fibrosis
Journal name European Respiratory Journal   Check publisher's open access policy
ISSN 0903-1936
Publication date 2006-02
Sub-type Article (original research)
DOI 10.1183/09031936.06.00069005
Volume 27
Issue 2
Start page 354
End page 358
Total pages 5
Place of publication Lausanne, Switzerland
Publisher European Respiratory Society
Language eng
Abstract Cystic fibrosis (CF) is characterised by inspissated airway secretions and chronic endobronchial infection associated with exuberant neutrophilic inflammation. Unfractionated heparin may be mucolytic and has demonstrated a number of anti-inflammatory properties; however, further safety data are needed in these subjects who are at risk of airway bleeding. The current study aimed to assess the medium-term safety and tolerability of moderately high-dose inhaled heparin in CF adults and to explore possible in vivo mucolytic and anti-inflammatory outcomes. A randomised, double-blind, placebo-controlled crossover study of twice daily inhalation of 50,000 IU of heparin for 2 weeks was undertaken in CF adults, with a 1-week washout period. Eighteen subjects were randomised and 14 (mean±sd age 23±7.8 yrs and percentage-predicted forced expiratory volume in one second 52.1±15.56%) completed the study protocol. Heparin neither affected blood coagulation parameters nor resulted in any increase in adverse events. Heparin inhalation had no significant effect upon forced expiratory volume in one second, symptoms of sputum clearance or sputum inflammatory markers. The current pilot study demonstrated no evidence of improved sputum clearance with 50,000 IU of inhaled heparin given twice daily to adult cystic fibrosis subjects. However, inhaled heparin was safe and the future evaluation of larger doses over a longer period may be warranted.
Keyword Cystic Fibrosis
Neutrophil elastase
Human Neutrophil Elastase
Recombinant Human Dnase
Airway Inflammation
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 16 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 13 Apr 2012, 11:53:45 EST by System User on behalf of School of Medicine